Eisai
4523.T
#2011
Rank
S$10.56 B
Marketcap
$37.48
Share price
-0.53%
Change (1 day)
-41.61%
Change (1 year)
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.

Revenue for Eisai (4523.T)

Revenue in 2024 (TTM): S$6.82 Billion

According to Eisai's latest financial reports the company's current revenue (TTM ) is S$6.85 Billion. In 2023 the company made a revenue of S$6.98 Billion a decrease over the revenue in the year 2022 that were of S$7.44 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Eisai from 2009 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$6.82 B-2.37%
2023 S$6.98 B-6.17%
2022 S$7.44 B-13.42%
2021 S$8.60 B-2.53%
2020 S$8.82 B7.93%
2019 S$8.17 B5.12%
2018 S$7.77 B14.59%
2017 S$6.78 B-4.69%
2016 S$7.12 B7.3%
2015 S$6.63 B-3.46%
2014 S$6.87 B-8.59%
2013 S$7.52 B-12.75%
2012 S$8.61 B-20.06%
2011 S$10.78 B-10.87%
2010 S$12.09 B3.15%
2009 S$11.72 B